EP1556072A4 - Ii-KEY/ANTIGENIC EPITOPE HYBRID PEPTIDE VACCINES - Google Patents

Ii-KEY/ANTIGENIC EPITOPE HYBRID PEPTIDE VACCINES

Info

Publication number
EP1556072A4
EP1556072A4 EP03789700A EP03789700A EP1556072A4 EP 1556072 A4 EP1556072 A4 EP 1556072A4 EP 03789700 A EP03789700 A EP 03789700A EP 03789700 A EP03789700 A EP 03789700A EP 1556072 A4 EP1556072 A4 EP 1556072A4
Authority
EP
European Patent Office
Prior art keywords
key
antigenic epitope
peptide vaccines
hybrid peptide
epitope hybrid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP03789700A
Other languages
German (de)
French (fr)
Other versions
EP1556072B1 (en
EP1556072A2 (en
Inventor
Robert E Humphreys
Minzhen Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Antigen Express Inc
Original Assignee
Antigen Express Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/245,871 external-priority patent/US20030235594A1/en
Priority claimed from US10/253,286 external-priority patent/US7179645B2/en
Application filed by Antigen Express Inc filed Critical Antigen Express Inc
Publication of EP1556072A2 publication Critical patent/EP1556072A2/en
Publication of EP1556072A4 publication Critical patent/EP1556072A4/en
Application granted granted Critical
Publication of EP1556072B1 publication Critical patent/EP1556072B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP03789700A 2002-09-17 2003-09-12 Ii-KEY/ANTIGENIC EPITOPE HYBRID PEPTIDE VACCINES Expired - Lifetime EP1556072B1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US245871 1981-03-23
US10/245,871 US20030235594A1 (en) 1999-09-14 2002-09-17 Ii-Key/antigenic epitope hybrid peptide vaccines
US253286 2002-09-24
US10/253,286 US7179645B2 (en) 2002-09-24 2002-09-24 Ii-Key/antigenic epitope hybrid peptide vaccines
PCT/US2003/028574 WO2004030616A2 (en) 2002-09-17 2003-09-12 Ii-KEY/ANTIGENIC EPITOPE HYBRID PEPTIDE VACCINES

Publications (3)

Publication Number Publication Date
EP1556072A2 EP1556072A2 (en) 2005-07-27
EP1556072A4 true EP1556072A4 (en) 2005-12-21
EP1556072B1 EP1556072B1 (en) 2010-05-19

Family

ID=32072825

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03789700A Expired - Lifetime EP1556072B1 (en) 2002-09-17 2003-09-12 Ii-KEY/ANTIGENIC EPITOPE HYBRID PEPTIDE VACCINES

Country Status (5)

Country Link
EP (1) EP1556072B1 (en)
JP (1) JP2006515744A (en)
AU (1) AU2003294220A1 (en)
CA (1) CA2499123A1 (en)
WO (1) WO2004030616A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601351B1 (en) 2002-06-26 2009-10-13 Human Genome Sciences, Inc. Antibodies against protective antigen
WO2006009920A2 (en) * 2004-06-17 2006-01-26 Mannkind Corporation Epitope analogs
ES2531483T3 (en) 2005-06-15 2015-03-16 The Ohio State University Research Foundation HER-2 peptides
US20080095798A1 (en) * 2006-10-18 2008-04-24 Robert Humphreys Ii-key enhanced vaccine potency
GB0706070D0 (en) * 2007-03-28 2007-05-09 Scancell Ltd Nucleic acids
US20100234283A1 (en) 2009-02-04 2010-09-16 The Ohio State University Research Foundation Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use
JP2012050440A (en) * 2011-09-16 2012-03-15 Chiba Univ Method of evaluating human th1/th2 differentiation induction
US11096994B2 (en) * 2012-10-30 2021-08-24 Aravax Pty Ltd Immunotherapeutic molecules and uses thereof
JP7007534B2 (en) 2013-09-25 2022-01-24 アラヴァックス ピーティーワイ リミテッド New immunotherapeutic composition and its use
RS64397B1 (en) * 2015-03-27 2023-08-31 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various tumors (seq id 25 - mrax5-003)
GB201507030D0 (en) * 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
SG11201808710UA (en) * 2016-04-19 2018-11-29 Imcyse Sa Novel immunogenic cd1d binding peptides
CN108129558B (en) * 2017-12-21 2021-10-12 中国医学科学院北京协和医院 Extraction, separation and purification method and application of main allergenic protein Bet v8 of birch pollen
US20230000908A1 (en) * 2019-09-11 2023-01-05 Ohio State Innovation Foundation Engineered cells and uses thereof
WO2023240295A2 (en) * 2022-06-10 2023-12-14 Ayass Bioscience Llc Food allergen processing and desensitization by aptamers

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559028A (en) * 1993-05-19 1996-09-24 Antigen Express, Inc. Methods of enhancing or antigen presentation to T cells inhibiting
US6432409B1 (en) * 1999-09-14 2002-08-13 Antigen Express, Inc. Hybrid peptides modulate the immune response

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4650764A (en) 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
EP0190205B1 (en) 1984-07-24 1992-10-21 Coselco Mimotopes Pty. Ltd. Method for determining mimotopes
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US6133029A (en) 1988-03-21 2000-10-17 Chiron Corporation Replication defective viral vectors for infecting human cells
US5194425A (en) 1988-06-23 1993-03-16 Anergen, Inc. Mhc-mediated toxic conjugates useful in ameliorating autoimmunity
ES2075196T3 (en) 1989-02-17 1995-10-01 Chiron Mimotopes Pty Ltd METHOD FOR USE AND SYNTHESIS OF PEPTIDES.
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5126132A (en) 1989-08-21 1992-06-30 The United States Of America As Represented By The Department Of Health And Human Services Tumor infiltrating lymphocytes as a treatment modality for human cancer
ATE212672T1 (en) 1989-10-24 2002-02-15 Chiron Corp SYSTEM FOR RELEASING INFECTIOUS PROTEINS
US5747334A (en) 1990-02-15 1998-05-05 The University Of North Carolina At Chapel Hill Random peptide library
ATE176239T1 (en) 1990-11-21 1999-02-15 Iterex Pharma Lp SYNTHESIS OF EQUIMOLAR MIXTURES OF VARIOUS OLIGOMERS, SPECIFICALLY OLIGOPEPTIDE MIXTURES
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
ATE152915T1 (en) 1991-11-29 1997-05-15 Viagene Inc IMMUNOTHERAPEUTIC VECTOR CONSTRUCTS AGAINST CANCER
US5679527A (en) 1992-03-25 1997-10-21 Antigen Express, Inc. Modification of polypeptide structure
AU5670194A (en) 1992-11-20 1994-06-22 Enzon, Inc. Linker for linked fusion polypeptides
DE69430315T2 (en) 1993-08-06 2002-11-21 Epimmune, Inc. METHODS FOR (EX VIVO) THERAPY BY MEANS OF PEPTIDE - ASSEMBLED ANTIQUE - PRESENTING CELLS FOR ACTIVATING CTL
US5874214A (en) 1995-04-25 1999-02-23 Irori Remotely programmable matrices with memories
DE69628731T3 (en) 1995-11-01 2012-09-20 Bracco Suisse S.A. TARGETED MAGNETICALLY MARKED MOLECULAR MARKER SYSTEMS AS NMR IMAGING PRODUCTS
AU3307497A (en) 1996-06-26 1998-01-14 Antigen Express, Inc. Immunotherapy by modulation of antigen presentation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559028A (en) * 1993-05-19 1996-09-24 Antigen Express, Inc. Methods of enhancing or antigen presentation to T cells inhibiting
US6432409B1 (en) * 1999-09-14 2002-08-13 Antigen Express, Inc. Hybrid peptides modulate the immune response

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO2004030616A2 *
XU M ET AL: "MHC class II allosteric site drugs: New immunotherapeutics for malignant, infectious and autoimmune diseases", SCANDINAVIAN JOURNAL OF IMMUNOLOGY, vol. 54, no. 1-2, July 2001 (2001-07-01), pages 39 - 44, XP002350848, ISSN: 0300-9475 *

Also Published As

Publication number Publication date
EP1556072B1 (en) 2010-05-19
WO2004030616A3 (en) 2004-10-07
EP1556072A2 (en) 2005-07-27
AU2003294220A8 (en) 2004-04-23
WO2004030616A2 (en) 2004-04-15
JP2006515744A (en) 2006-06-08
AU2003294220A1 (en) 2004-04-23
CA2499123A1 (en) 2004-04-15

Similar Documents

Publication Publication Date Title
GB2463586B (en) li-key/antigenic epitope hybrid peptide vaccines
IL176006A0 (en) Immunogenic peptide carrier conjugates and methods for producing the same
AU2003299535A8 (en) Group b streptococcus vaccine
AU2003294220A8 (en) Ii-key/antigenic epitope hybrid peptide vaccines
EP1337149A4 (en) Vaccine immunotherapy for immune suppressed patients
EP1550453A4 (en) Cancer antigen peptide preparation
GB0225788D0 (en) Vaccine
EP1558628A4 (en) Antigenic peptides
AU2003285320A8 (en) Vaccine
GB0212046D0 (en) Vaccines
AU2003228863A8 (en) Immunogenic peptides
GB0228715D0 (en) Vaccine
AU2003264724A8 (en) Flagellin peptides as adjuvants for vaccines
AU2002365187A8 (en) Epitope synchronization in antigen presenting cells
AU2003237701A8 (en) Vaccines
GB0313064D0 (en) Mycobacterial vaccine
GB0206595D0 (en) Vaccine
GB0025775D0 (en) Antigenic peptides
GB0223355D0 (en) Vaccine
GB0226179D0 (en) Vaccine
GB0200349D0 (en) Antigenic polypeptides
ITMI20020433A1 (en) GP100 / PME117 ANTIGENIC EPITOPES
HK1057318A (en) Vaccine immunotherapy for immune suppressed patients
GB0200829D0 (en) Vaccines
GB0217721D0 (en) Vaccines

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050418

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

A4 Supplementary search report drawn up and despatched

Effective date: 20051108

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20060320

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 60332645

Country of ref document: DE

Date of ref document: 20100701

Kind code of ref document: P

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20100519

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100830

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100519

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100519

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100519

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100519

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100820

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100519

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100920

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100519

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100519

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100519

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100519

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100519

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100519

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100519

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100519

26N No opposition filed

Effective date: 20110222

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100930

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 60332645

Country of ref document: DE

Effective date: 20110221

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100930

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100912

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100519

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101120

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100912

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100519

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100819

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20150226

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20150226

Year of fee payment: 12

Ref country code: FR

Payment date: 20150217

Year of fee payment: 12

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 60332645

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20150912

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20160531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160401

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150912

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150930